Novartis AG Profit Margin 2006-2019 | NVS

Current and historical gross margin, operating margin and net profit margin for Novartis AG (NVS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Novartis AG net profit margin as of June 30, 2019 is 23.27%.
Novartis AG Annual Profit Margins
Novartis AG Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $205.316B $51.900B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $344.226B 14.99
Roche Holding AG (RHHBY) Switzerland $232.232B 0.00
Merck (MRK) United States $213.305B 17.54
Pfizer (PFE) United States $206.197B 12.14
Novo Nordisk (NVO) Denmark $117.619B 20.78
AstraZeneca (AZN) United Kingdom $112.559B 21.78
Sanofi (SNY) France $109.681B 13.48
Eli Lilly (LLY) United States $107.617B 20.08
AbbVie (ABBV) United States $104.721B 8.39
GlaxoSmithKline (GSK) United Kingdom $102.338B 12.86
Bristol-Myers Squibb (BMY) United States $81.150B 11.51
Bayer (BAYRY) Germany $70.202B 10.23
H Lundbeck (HLUYY) Denmark $7.119B 10.27